免疫检查点抑制剂在儿童肿瘤中的应用
帕博利珠单抗说明书推荐剂量
纳武单抗说明书推荐剂量
儿童推荐剂量:≥40kg推荐240mg Q2W或者480mg Q4W;<40mg推荐3mg/kgQ2W;
儿童适用瘤种:MSI-H/dMMR转移结直肠癌
K药治疗儿童晚期黑色素瘤或PD-L1阳性、晚期复发/难治性实体瘤、淋巴瘤(KEYNOTE-051)
O药治疗复发或难治性非CNS实体瘤或淋巴瘤(ADVL1412研究)
在淋巴瘤患者中观察到缓解(所有应答者均具有PD-L1表达):
在10例cHL中,1例CR,2例PR,5例SD,2例靶病灶减小却出现新病灶。 在10例NHL中,有1例纵膈大B淋巴瘤PET检测达到代谢完全缓解,根据RECIST V1.1标准评判为PR。
T药治疗儿童复发性或难治性实体瘤或淋巴瘤(iMATRIX)
1. KEYTRUDA® (pembrolizumab) injection, for intravenous use药品说明书 .
2. OPDIVO (nivolumab) injection, for intravenous use药品说明书.
3. Geoerger B, Kang HJ, Yalon-Oren M, et al. Pembrolizumab inpaediatric patients with advanced melanoma or a PD-L1-positive, advanced,relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interimanalysis of an open-label, single-arm, phase 1-2 trial. Lancet Oncol.2020;21(1):121-133. doi:10.1016/S1470-2045(19)30671-0.
4. Davis KL, Fox E, Merchant MS, et al. Nivolumab in children and youngadults with relapsed or refractory solid tumours or lymphoma (ADVL1412): amulticentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol.2020;21(4):541-550. doi:10.1016/S1470-2045(20)30023-1.
5. Geoerger B, Zwaan CM, Marshall LV, et al. Atezolizumab for childrenand young adults with previously treated solid tumours, non-Hodgkin lymphoma,and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study. Lancet Oncol.2020;21(1):134-144. doi:10.1016/S1470-2045(19)30693-X.
6. Response-Adapted Therapy with Nivolumab + Brentuximab Vedotin inChildren, Adolescents, and Young Adults with Standard-Risk Relapsed/RefractoryClassical Hodgkin Lymphoma: Checkmate 744.(EHA 摘要号:S224).
7. Cacciotti, C., Choi, J., Alexandrescu, S. et al. Immune checkpointinhibition for pediatric patients with recurrent/refractory CNS tumors: asingle institution experience. J Neurooncol (2020). https://doi.org/10.1007/s11060-020-03578-6.
8. Wang SS, Bandopadhayay P, Jenkins MR. Towards Immunotherapy forPediatric Brain Tumors. Trends Immunol. 2019;40(8):748-761.doi:10.1016/j.it.2019.05.009.
精彩推荐:
- End -